GSK plc
GSK · Healthcare
$50.66
Caricamento grafico…
Notizie
Ultime notizie su questo titolo
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
Moderna secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine, establishing a foothold in the multibillion-dollar flu vaccine market. However, GSK announced plans to advance its own mRNA flu vaccine into phase III trials, which targets two viral proteins (HA and NA) and showed superior immune responses in phase II studies. While GSK's vaccine is still years away from market approval, it could pose a competitive challenge to Moderna's mFlusiva, which currently targets only HA like traditional flu vaccines.
GSK to Advance mRNA Influenza Vaccine Into Phase III Development
GSK announced it will begin a Phase III efficacy study of its mRNA-based seasonal flu vaccine in September 2026, following positive Phase II results showing higher immune responses than standard and high-dose flu vaccines. The vaccine uniquely targets both HA and NA antigens, unlike most existing flu vaccines. The FDA granted Fast Track designation to the candidate. Moderna's mFlusiva mRNA flu vaccine was recently approved by the FDA for adults 50+.
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
Gilead Sciences received FDA approval for Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults unable to take current treatments. The company raised its 2026 HIV sales growth outlook to 9-10%, driven by flagship drugs Biktarvy, Descovy, and the rapidly growing Yeztugo injectable PrEP. Bixlenvo and Gilead's expanding lenacapavir pipeline offer additional growth opportunities in HIV treatment and prevention.
AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
The article compares AbbVie and Eli Lilly as pharmaceutical investment options for 2026. AbbVie focuses on immunology and neuroscience with revenue of $61.2B and faces patent expiration risks, while Eli Lilly is experiencing explosive 45% revenue growth driven by its GLP-1 drugs (Mounjaro and Zepbound) with projected 2026 revenue of $85.2B. Despite Eli Lilly's higher valuation, the article recommends it for long-term investors due to the sustained demand and lifecycle nature of its metabolic therapies.
State of the Life Sciences Industry to Be Reviewed in BCC Research's 2026 Second Quarter Outlook, Spotlighting AI-Driven Discovery, Precision Oncology, and Connected Health Adoption
BCC Research's mid-year assessment highlights AI-driven discovery, precision oncology, and connected health as major growth themes in the life sciences sector. Key opportunities include smart inhalers with AI integration, genomic profiling platforms, cardiovascular drug innovations, and in vitro toxicity testing. The sector benefits from aging populations, regulatory support for non-animal testing, and emerging market expansion, though risks include patent expirations and reimbursement variability.